Enalapril prophylaxis for migraine with aura

Headache

Volumn 43, Issue 2, 2003, Pages 170-

  Camarda, Rosolino ^a   Monastero, Roberto ^a   Mannino, Marina ^a   Camarda, Cecilia ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IBUPROFEN;

AGED; CASE REPORT; CLINICAL FEATURE; DRUG INDICATION; DRUG MECHANISM; EPILEPTIC AURA; FEMALE; HUMAN; HYPERTENSION; LETTER; MIGRAINE; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENALAPRIL; FEMALE; HUMANS; MIGRAINE WITH AURA;

EID: 0037318108     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2003.03038.x     Document Type: Letter

References (6)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
2. Govantes C, Marin J. Effect of angiotensin converting enzyme inhibitors on quality of life in hypertensive patients. Pharmacodynamic basis. Fundam Clin Pharmacol. 1996;10:400-405.
3. Sicuteri F. Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache). Cephalalgia. 1981;1:229-232.
4. Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache. 1995;35:470-471.
5. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322: 19-22.
6. Paterna S, Di Pasquale P, D'Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol. 2000;43:133-136.